PROXIME
Proxime builds a device to make it faster and easier to alter cells with beneficial DNA. The device forces the viral vector and the cells into direct contact by organizing them into a space as thin as human hair. That means far less of the costly vector is needed. Proxime’s device can create 1 billion altered cells at a time, six times faster than conventional approaches and with one-fourth the amount of vector. The result will be more accessible, affordable gene therapy.
PROXIME
Industry:
Biotechnology Genetics Life Science
Founded:
2021-01-01
Status:
Active
Total Funding:
67.09 K USD
Similar Organizations
KOLIBRI
Next-generation cell-culture platform to unlock biologics manufacturing, starting with gene therapies
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Proxime
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Proxime